Who founded Alloplex Biotherapeutics?

Alloplex Biotherapeutics was founded by Francescopaolo Borriello, Frank Borriello.

Who are Alloplex Biotherapeutics's investors?

Alloplex Biotherapeutics's investors include Hackensack Meridian Health Bear's Den.

How much funding has Alloplex Biotherapeutics raised?

Alloplex Biotherapeutics has disclosed $21.1M raised across 3 rounds.

Where is Alloplex Biotherapeutics headquartered?

Alloplex Biotherapeutics is headquartered in Boston, US.

Alloplex Biotherapeutics

Boston, US · Delaware corporation · 1 known investors

Alloplex Biotherapeutics develops a non-engineered autologous cellular therapy for cancer, built on its ENLYST immune cell training platform and lead candidate SUPLEXA, which trains a patient's peripheral blood cells ex vivo to create anti-tumor therapeutic cells. The company operates in the immuno-oncology and cell therapy space and has completed a Phase 1 clinical trial across multiple tumor types.

Biotech Deep Tech Healthtech Medical Devices

Founders & leadership

Francescopaolo BorrielloCo-founder

Frank BorrielloFounder & Scientific Founder

James LedererChief Scientific Officer (CSO)

Sharron GargoskyChief Development Officer

Investors · 1

Hackensack Meridian Health Bear's DenIselin · $250K – $1M

Reported raises · per SEC filings

Form D private placements

$21.1M disclosed across 3 rounds · 2018–2023

▶$20.7MraisedFeb 2023 · 51 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Francescopalo BorrielloExecutive Officer

Offering amount: $25M
Amount sold: $20.7M
First sale: Jan 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$200KraisedJul 2019 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Francescopaolo BorrielloExecutive Officer, Director

Amount sold: $200K
First sale: Jul 2019
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$200KraisedJan 2019 · 2 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Francescopaolo BorrielloExecutive Officer, Director

Offering amount: $2M
Amount sold: $200K
First sale: Dec 2018
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Immunomic Therapeutics14 shared keywordsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.

Companies competing with Alloplex Biotherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Alloplex Biotherapeutics do?: Alloplex Biotherapeutics develops a non-engineered autologous cellular therapy for cancer, built on its ENLYST immune cell training platform and lead candidate SUPLEXA, which trains a patient's peripheral blood cells ex vivo to create anti-tumor therapeutic cells. The company operates in the immuno-oncology and cell therapy space and has completed a Phase 1 clinical trial across multiple tumor types.
Who founded Alloplex Biotherapeutics?: Alloplex Biotherapeutics was founded by Francescopaolo Borriello, Frank Borriello.
Who are Alloplex Biotherapeutics's investors?: Alloplex Biotherapeutics's investors include Hackensack Meridian Health Bear's Den.
How much funding has Alloplex Biotherapeutics raised?: Alloplex Biotherapeutics has disclosed $21.1M raised across 3 rounds.
Where is Alloplex Biotherapeutics headquartered?: Alloplex Biotherapeutics is headquartered in Boston, US.